Due to the co-existing prostate-specific antigen (PSA) raising and lowering factors, the commonly used PSA screening test often lacks sufficient sensitivity or specificity to accurately predict prostate cancer (PCa).¹ Spermine, a novel non-prostate massage urine biomarker, was recently shown to be

Mitomycin gel is approved by the United States Food and Drug Administration (FDA) as the first non-surgical treatment for patients with low-grade upper tract urothelial cancer (UTUC).¹ Results from the OLYMPUS, an open-label, single-arm and phase 3 clinical trial,

Based on the Prostate Cancer Working Group (PCWG) 3 consensus, prostate cancer patients are considered castration-resistant when a minimum rise of 2ng/mL in prostate-specific antigen (PSA) level is observed after androgen depletion therapy (ADT).1 Previously, castration-resistant prostate cancer pat